Arrowhead Research Corporation - 10-Q Summary
Business Context and Reporting Period
Company: Arrowhead Research Corporation (a development stage nanotechnology company).
Reporting Period: Quarterly period ended March 31, 2008 (Second Quarter of Fiscal 2008).
Business Model: Operates a portfolio of five majority-owned subsidiaries (Insert Therapeutics, Calando Pharmaceuticals, Unidym, Tego BioSciences, and Aonex Technologies) to commercialize nanotechnology in life sciences, electronics, and energy. The company also funds sponsored university research to secure intellectual property rights.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Six Months Ended Mar 31, 2008 |
|---|---|---|
| Revenue | $729,766 | $1,132,627 |
| Net Loss | $(5,694,815) | $(10,928,589) |
| Operating Loss | $(7,072,689) | $(13,957,812) |
| Cash and Cash Equivalents | $19,522,301 (as of Mar 31, 2008) | N/A |
| Net Cash Used in Operating Activities | N/A | $(11,546,040) |
| Accumulated Deficit | $(69,336,026) | N/A |
Revenue Composition (Six Months): Primarily derived from grants ($748,487) and sales of carbon nanotubes ($362,740) via the Unidym subsidiary. Prior year revenue was negligible ($7,394).
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the three months ended March 31, 2008, decreased to $5.7 million from $6.2 million in the prior year period. The six-month loss increased to $10.9 million from $9.9 million, driven by increased headcount and R&D scaling at Unidym.
- Revenue Growth: Revenue increased significantly from a reversal of $(3,697) in the prior year quarter to $729,766, driven by Unidym's commercialization of carbon nanotubes and grant funding.
- Expense Shifts: Operating expenses remained relatively flat quarter-over-quarter ($7.4 million vs. $7.5 million), but the composition shifted. Salaries increased due to hiring at Unidym and corporate levels, while outside lab and contract services decreased significantly as Insert and Calando streamlined operations following IND filings.
- Stock-Based Compensation: Increased to $852,000 for the quarter (from $484,000 prior year) due to an inducement grant to the new CEO.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Clinical Progress: Insert Therapeutics filed a second IND for a Phase II trial of IT-101 (ovarian cancer) in April 2008. Calando Pharmaceuticals received FDA approval to commence a Phase I trial of CALAA-01 in March 2008.
- Merger Activity: Insert and Calando merged on April 17, 2008, to streamline operations and combine technologies. Aonex Technologies was sold to AmberWave Systems Corporation on May 5, 2008.
- Liquidity: Management believes cash on hand ($19.5 million) is sufficient to fund operations through the fourth quarter of fiscal 2008. An S-3 registration statement allows for up to $50 million in future equity offerings.
Risks and Contingencies:
- Capital Needs: The company expects to continue incurring operating losses and will require additional capital to fund clinical trials and R&D. Failure to raise capital could force a reduction in activities.
- Lease Uncertainty: Unidym's Houston facility lease expired, and the landlord is unwilling to renew, creating a risk of relocation costs and operational disruption.
- Regulatory Risk: Success depends on FDA approvals and third-party reimbursement policies, which are subject to change.
Investor Verification Checklist
- Cash Runway: Verify if the $19.5 million cash balance is sufficient to cover the projected $6 million capital commitment to the merged Insert/Calando entity and ongoing R&D burn rates through Q4 2008.
- Subsidiary Merger Impact: Confirm the financial and operational integration status of the April 2008 Insert/Calando merger and the repayment of intercompany loans.
- Aonex Sale Terms: Review the earn-out structure of the Aonex sale to AmberWave Systems, noting that Arrowhead has preference on the first $6.3 million of payments.
- Unidym Relocation: Assess the potential costs and timeline for relocating Unidym's Houston manufacturing operations due to the lease non-renewal.
- Stock-Based Compensation: Monitor the vesting schedule and expense impact of the 2 million share inducement grant to the CEO.